A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT04607148 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
144
Enrollment
INDUSTRY
Sponsor class

Stopped The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).

Conditions

Interventions

Sponsor

Genentech, Inc.